Here are the 10-Q quarterly reports from LeonaBio, Inc. (LONA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LONA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LONA filings page.
LeonaBio, Inc. is a clinical-stage biopharmaceutical company developing lasofoxifene for ESR1-mutated metastatic breast cancer and brelgometon for ALS. For the six months ended June 30, 2026, it reported a net loss of $51.9 million, significantly higher than $16.1 million a year earlier, driven by much higher research and development and general and administrative spending.
Cash, cash equivalents and investments totaled $51.1 million at June 30, 2026, down from $69.9 million at year-end, with $37.9 million used in operating activities in the first half. The company states that existing liquidity may not fund operations for at least 12 months, raising substantial doubt about its ability to continue as a going concern.
LeonaBio raised $90.0 million in a December 2025 PIPE, issuing common stock and multiple warrant classes, including 23.0 million Series A Common Warrants that, if fully exercised, could provide an additional $146.2 million. A 5.5 million-share Sermonix pre-funded warrant was reclassified from liability to equity after stockholder approval, eliminating a large fair value liability from the balance sheet.
LeonaBio, Inc., a clinical-stage biopharma company, reported a net loss of $32.9M for the quarter ended March 31, 2026, compared with $9.1M a year earlier. The larger loss was driven by higher research and development spending and a $16.3M non-cash loss from remeasuring the Sermonix pre-funded warrant before it was reclassified to equity.
Research and development expenses rose to $11.3M, mainly reflecting investment in lasofoxifene and ATH-1105, while general and administrative costs increased to $6.9M. Cash, cash equivalents and investments totaled $67.7M, and management believes this will fund operations for at least 12 months based on the current plan.